Include Cy-Tb injection in national TB elimination programme: SII urges MoHFW

Published On 2022-07-05 07:51 GMT | Update On 2022-07-05 07:51 GMT

New Delhi: Serum Institute has requested the Union health ministry for inclusion of their Cy-Tb injection for detection of Latent-TB in the National TB Elimination Programme (NTEP) to support TB free-India by 2025, official sources said on Monday. The Serum Institute had recently informed the ministry that the firm would provide Cy-Tb injection at Rs 350 plus GST per dose, an official source stated.

The letter for the inclusion of Cy-Tb was written by Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII.

The Cy-Tb injection was granted market authorisation by the Drugs Controller General of India (DCGI) on May 9, 2022.

In response to Singh's request, the Ministry of Health and Family Welfare (MoHFW) had sought the price of Cy-Tb injection. Serum Institute has informed MoHFW that the firm will provide Cy-Tb injection at Rs 350 plus GST per dose, an official source stated.

Read also: COVID-19: DCGI nod to Gennova's indigenous mRNA vaccine for emergency use in 18 years and above; SII's Covovax for 7-11 years

According to official sources, the ministry has not taken any decision on procurement of this product as there are few programmatic challenges in Cy-Tb kit of Serum Institute.

Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs.TB is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected.

India is committed to eliminate tuberculosis by 2025, five years ahead of the target for TB elimination set by Sustainable Development Goals 2030.

Serum Institute of India is an Indian biotechnology and biopharmaceuticals company headquartered in Pune, India. The company was founded by Dr. Cyrus Poonawalla in 1966.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Include Cy-Tb injection in national TB elimination programme: SII urges MoHFW

Similar News

Russia's Enteromix Cancer Vaccine Shows 100% Success in Trial, Awaits Final Nod for Public Use

Mankind Pharma wins CDSCO nod to start Phase 1 trials of Autoimmune drug candidate

India seeks to boost drug exports to semi regulated markets in Africa, Latin America, Southeast Asia

Jubilant Ingrevia appoints Sonia Dharap as Vice President - Sales, Business Development (US)

EMA warns of sharp rise in illegal medicines sold in EU

Indegene opens new center in Pune, boosts India presence

Indian medical devices share increased from 10% to 30% of domestic requirements in last 5 years: DoP Secretary

AstraZeneca announces Rs 176 crore investments in India to expand Chennai GITC